Novel anxiety mechanism class enters late-stage trials
Anxiolytic late-stage programs targeting GABAergic, glutamatergic, and neurosteroid pathways are reading out after decades of SSRI dominance.
Generalised anxiety disorder has been an SSRI and benzodiazepine story for decades. Late-stage programs targeting novel mechanisms (positive allosteric modulators, neurosteroids, glutamate-pathway agents) are now reading out. Tolerability and abuse-potential profiles will define which programs land routine prescribing versus niche use.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedDigital therapeutics in mental health: access, evidence, and what reimbursement looks like
- SnapshotBipolar disorder treatment landscape, 2026 mid-year reference
- ExplainedHow pediatric mental health prescribing differs from adult and why it matters
- SnapshotTreatment-resistant depression pipeline, 2026 mid-year reference
TreatmentPipelineDrug development
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.